- About Us
- Nano-Social Network
- Nano Consulting
- My Account
April 4th, 2007
n health sector news, Australian bio-nanotech Psivida Ltd. surged 80 cents, or 39.2 percent, to $2.84 in the early session after signing an exclusive research and license agreement for its drug delivery technology with Pfizer Inc.
Under the agreement, which centers on ophthalmic, or eye-care products, Psivida will receive up to $155 million in development and sales-related milestone payments, and royalties on future products.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers